1. Buglione M, Jereczek-Fossa BA, et al. (2020) Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent. Lung Cancer, 141: 1-8. [DOI:10.1016/j.lungcan.2019.12.019] [PMID]

2. Ricardi U, Frezza G, et al. (2014) Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer, 84: 248-53. [DOI:10.1016/j.lungcan.2014.02.015] [PMID]

3. Macià i Garau M (2017) Radiobiology of stereotactic body radiation therapy (SBRT). Rep Pract Oncol Radiother, 22(2): 86-95. [DOI:10.1016/j.rpor.2017.02.010] [PMID] []

4. Finkelstein SE and Timmerman R (2011) The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol, 439752. [DOI:10.1155/2011/439752] [PMID] []

5. Reynders K, Illidge T, et al. (2015) The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev, 41(6): 503-10. [DOI:10.1016/j.ctrv.2015.03.011] [PMID] []

6. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 4(1): 11-22. [DOI:10.1038/nrc1252] [PMID]

7. Bhalla N, Brooker R, et al. (2018) Combining immunotherapy and radiotherapy in lung cancer. J Thorac Dis, 10(13): S1447-S1460. [DOI:10.21037/jtd.2018.05.107] [PMID] []

8. Liu S, Sun X, et al. (2015) Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res, 5(11): 3276-3285.

9. Lhuillier C, Rudqvist NP, et al. (2019) Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med, 11(1): 40. [DOI:10.1186/s13073-019-0653-7] [PMID] []

10. Apetoh L, Ghiringhelli F, et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy; NatureMedicine, 13(9): 1050-1059.

11. Ngwa W, Irabor OC, et al. (2018) Using immunotherapy to boost the abscopal effect. Nat Rev Cancer, 18(5): 313-322. [DOI:10.1038/nrc.2018.6] [PMID] []

12. Bernstein MB and Krishnan S, et al. (2016) Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol, 13: 516-524. [DOI:10.1038/nrclinonc.2016.30] [PMID] []

13. Yilmaz MT, Elmali A, et al. (2019) Abscopal effect, from myth to reality: From radiation oncologists' perspective. Cureus, 11(1): e3860. [DOI:10.7759/cureus.3860] [PMID] []

14. Marconi R, Strolin S, et al. (2017) A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? PLoS One, 12(2): e0171559. [DOI:10.1371/journal.pone.0171559] [PMID] []

15. Dewan MZ, Galloway AE, et al. (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res, 15: 5379-88. [DOI:10.1158/1078-0432.CCR-09-0265] [PMID] []

16. Demaria S, Formenti SC, et al. (2012) Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol, 2: 153. [DOI:10.3389/fonc.2012.00153] [PMID] []

17. Borghetti P, Bonù ML, et al. (2019) Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiol Med, 124(7): 662-670. [DOI:10.1007/s11547-019-00999-w] [PMID]

18. Borghetti P, Bonù ML, et al. (2018) Radiotherapy and tyrosine kinase inhibitors in stage IV non-small cell lung cancer: Real-life experience. In Vivo, 32(1): 159-164. [DOI:10.21873/invivo.11219]

19. Martinez P, Peters S, et al. (2019) Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer. Clin Cancer Res, 25(9): 2691-2698. [DOI:10.1158/1078-0432.CCR-18-3904] [PMID]

20. Kim W, Lee S, et al. (2019) Cellular stress responses in radiotherapy. Cells, 8(9): 1105. [DOI:10.3390/cells8091105] [PMID] []

21. Bubici C and Papa S, et al. (2006) Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene, 25(51): 6731-48. [DOI:10.1038/sj.onc.1209936] [PMID]

22. Shakibaei M, Schulze-Tanzil G, et al. (2005) Redox regulation of apoptosis by members of the TNF superfamily. Antioxid Redox Signal, 7(3-4): 482-96. [DOI:10.1089/ars.2005.7.482] [PMID]

23. Chen Y, Williams J, et al. (2002) Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol, 12(1 - 1): 26-33. [DOI:10.1053/srao.2002.31360] [PMID]

24. Lierova A, Jelicova M, et al. (2018) Cytokines and radiation-induced pulmonary injuries. J Radiat Res, 59(6): 709-753. [DOI:10.1093/jrr/rry067] [PMID] []

25. Silva EM, Mariano VS, et al. (2017) High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer. PLoS One, 12(7): e0181125. [DOI:10.1371/journal.pone.0181125] [PMID] []

26. De Vita F, Orditura M, et al. (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest, 117: 365-73. [DOI:10.1378/chest.117.2.365] [PMID]

27. Wang S, Chen J, et al. (2015) Prognostic value of cytokine profile on survival in non-small cell lung cancer patients treated with radiotherapy. Journal of Clinical Oncology, 33: 15_suppl, 7525-7525. [DOI:10.1200/jco.2015.33.15_suppl.7525]

28. Trovo M, Giaj-Levra N, et al. (2016) Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study. Clin Transl Oncol, 18(10): 1003-10. [DOI:10.1007/s12094-015-1473-x] [PMID]

29. Zhang T, Yu H, et al. (2017) Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. Sci Rep, 7(1): 4866. [DOI:10.1038/s41598-017-04978-x] [PMID] []

30. Ellsworth SG, Rabatic BM, et al. (2017) Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy. PLoS One, 12(9): e0183239. [DOI:10.1371/journal.pone.0183239] [PMID] []

31. McGee HM, Daly ME, et al. (2018) Stereotactic ablative radiation therapy induces systemic differences in peripheral blood immunophenotype dependent on irradiated site. Int J Radiat Oncol Biol Phys, 101(5): 1259-1270. [DOI:10.1016/j.ijrobp.2018.04.038] [PMID] []

32. Radin DP, Patel P, et al. (2017) BDNF: An oncogene or tumor suppressor? Anticancer Res, 37(8): 3983-3990. [DOI:10.21873/anticanres.11783]

33. Calabrese F, Rossetti AC, et al. (2014) Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci, 8: 430. [DOI:10.3389/fncel.2014.00430] [PMID] []

34. Luo X, Yu Y, et al. (2004) Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells. Cell Mol Immunol, 1(3): 199-204.

35. Li L, Liu YD, et al. (2018) High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma. Thorac Cancer, 9(7): 775-784. [DOI:10.1111/1759-7714.12643] [PMID] []

36. Aldinucci D, Colombatti A, et al. (2019) The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm, 2014: 292376. [DOI:10.1155/2014/292376] [PMID] []

37. Zhou W, Guo S, et al. (2019) Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Curr Med Chem, 26(17): 3026-3041. [DOI:10.2174/0929867324666170830111531] [PMID] []

38. Barinov A, Luo L, et al. (2017) Essential role of immobilized chemokine CXCL12 in the regulation of the humoral immune response. USA. Proc Natl Acad Sci, 114(9): 2319-2324. [DOI:10.1073/pnas.1611958114] [PMID] []

39. Zhang N, Hu H, et al. (2018) The overexpression of PDGF-BB and its receptor is correlated with lymphatic metastasis in patients with non-small cell lung cancer. Int J Clin Exp Pathol, 11(12): 6010-6017.

40. Albonici L, Giganti MG, et al. (2019) Multifaceted role of the placental growth factor (PlGF) in the antitumor immune response and cancer progression. Int J Mol Sci, 20(12). [DOI:10.3390/ijms20122970] [PMID] []

41. Kiang JG, Smith JT, et al. (2018) Circulating cytokine/chemokine concentrations respond to ionizing radiation doses but not radiation dose rates: Granulocyte-colony stimulating factor and interleukin-18. Radiat Res, 189(6): 634-643. [DOI:10.1667/RR14966.1] [PMID] []

42. Willett CG, Duda DG, et al. (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol, 27(18): 3020-6. [DOI:10.1200/JCO.2008.21.1771] [PMID] []

43. Aloe L, Rocco ML, et al. (2016) Nerve growth factor: role in growth, differentiation and controlling cancer cell development. J Exp Clin Cancer Res, 35: 116. [DOI:10.1186/s13046-016-0395-y] [PMID] []

44. Burgos-Ramos E and Martos-Moreno G (2012) Multiplexed bead immunoassays: Advantages and limitations in pediatrics. Advances in Immunoassay Technology. 2012; DOI: 10.5772/36024 [DOI:10.5772/36024]

45. de Jager W, Bourcier K , et al. (2009) Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol, 10: 52. [DOI:10.1186/1471-2172-10-52] [PMID] []

46. Tighe PJ, Ryder RR, et al. (2015) ELISA in the multiplex era: potentials and pitfalls. Proteomics Clin Appl, 9(3-4): 406-22. 10.1002/prca.201400130. [DOI:10.1002/prca.201400130] [PMID] []